Page 8 - 18F-FDG PET as biomarker in aggressive lymphoma; technical and clinical validation
P. 8
Contents
Chapter 1 Chapter 2
Chapter 3
Chapter 4
Chapter 5
Chapter 6a
General introduction 9
Part I PET as biomarker of response in lymphoma 25
FDG-PET as a biomarker for early response in diffuse 27 large B-cell lymphoma as well as in Hodgkin lymphoma?
Ready for implementation in clinical practice?
Haematologica. 2016 Nov;101(11):1279-1283.
Predictive value of interim positron emission tomography 41 in diffuse large B-cell lymphoma: a systematic review
and meta-analysis. Eur J Nucl Med Mol Imaging. 2019 Jan;46(1):65-79.
Part II Technical validation of PET in lymphoma 75
Interobserver Agreement of Interim and End-of- 77 Treatment 18F-FDG PET/CT in Diffuse Large B-Cell Lymphoma: Impact on Clinical Practice and Trials. J Nucl
Med. 2018 Dec;59(12):1831-1836.
Optimizing Workflows for Fast and Reliable Metabolic 101 Tumor Volume Measurements in Diffuse Large B Cell Lymphoma. Mol Imaging Biol. 2020 Aug;22(4):1102-
1110.
Part III Clinical validation of PET in lymphoma 123
18F-FDG PET Improves Baseline Clinical Predictors 125 of Response in Diffuse Large B-cell Lymphoma: The HOVON-84 Study. J Nucl Med. 2022 Jul;63(7):1001-
1007.
